Multicare Pharmaceuticals Philippin Pharmaceutical Import Profile — Philippines (DGFT 2022–2026)

Name: Multicare Pharmaceuticals Philippin Pharmaceutical Import Records from India — 5 Products, $1.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Multicare Pharmaceuticals Philippin — Pharmaceutical Importer Profile (2026) | 5 Products, $1.8M Trade | TransData Nexus

Multicare Pharmaceuticals Philippin

Pharmaceutical Importer · Philippines · Oncology Focus · $1.8M Total Trade · DGFT Verified

Multicare Pharmaceuticals Philippin is a pharmaceutical importer based in Philippines with a total trade value of $1.8M across 5 products in 3 therapeutic categories. Based on 60 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Multicare Pharmaceuticals Philippin sources from 3 verified Indian suppliers, with Naprod Life Sciences Private Limited accounting for 88.2% of imports.

Multicare Pharmaceuticals Philippin — Import Portfolio & Supplier Network

Multicare Pharmaceuticals Philippin import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Multicare Pharmaceuticals Philippin?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Naprod Life Sciences Private Limited	$3.0M	136	88.2%
Lupin Limited	$350.0K	7	10.3%
Olive Healthcare	$50.0K

What Formulations Does Multicare Pharmaceuticals Philippin Import?

Formulation	Value	Ships
Furic 40-10x10t(export)(febuxostat tabs40mg)bt#ja00915 to ja00924,mfg#04.2024,exp#03.2026(others-medicine put up for	$150.0K	3
Zildox-50 (oxaliplatin for injection	$100.0K	2
Naproplat 450MG/45ML carboplatin	$100.0K	2
L-aspase 10000 IU l-asparaginase for	$100.0K	2
Furic 80 - 10 x 10t (export) febuxostattablets 80 MG others-medicine put up forretail	$100.0K	2
Letoripe letrozole tablets usp2.5MG	$95.1K	3
Napro-tax 260MG/43.34ML paclitaxel	$64.0K	2
L-aspase 10000 IU (l-asparaginase for	$61.8K	2
Naproplat 450MG/45ML (carboplatin	$56.5K	2
Naproplat 150MG/15ML carboplatin injection BP 150MG/15ML	$51.7K	2
Anzol (anastrazole tablets 1MG) (3450	$50.0K	1
Naprocap 500 (capecitabine tablets USP	$50.0K	1
Letoripe (letrozole tablets USP 2.5MG)	$50.0K	1
Naproplat 450MG 45ML carboplatin injection BP 450MG 45ML 5090	$50.0K	1
L-aspase 10000 IU (l-asparaginase for	$50.0K	1

Multicare Pharmaceuticals Philippin imports 112 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Carboplatin	Oncology	$786.8K	16	1.1%	12
2	Febuxostat	Lipid & Metabolism	$350.0K	7	0.7%	6
3	Letrozole	Advanced Oncology	$350.0K	7	1.1%	8
4	Cytarabine	Advanced Oncology	$291.6K	25	2.7%	7
5	Dacarbazine	Advanced Oncology	$65.9K	5	4.6%	2

Multicare Pharmaceuticals Philippin imports 5 pharmaceutical products across 3 categories into Philippines totaling $1.8M.

Multicare Pharmaceuticals Philippin — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Multicare Pharmaceuticals Philippines, Inc. is a prominent pharmaceutical company headquartered in Makati City, Philippines. Established in 2002, it began as a division of Astra Philippines Inc. in 1998 and later became an independent entity. In 2009, Multicare formed a strategic alliance with Lupin Limited, a leading global pharmaceutical company based in India. This partnership has significantly bolstered Multicare's position in the Philippine pharmaceutical market, enabling it to offer a diverse range of high-quality medicines across various therapeutic areas. (multicare.com.ph)

Multicare's mission is to provide value to family healthcare by delivering quality and affordable medicines trusted by healthcare professionals nationwide. The company operates in multiple therapeutic areas, including oncology, rheumatology, respiratory, and women's health, among others. With over 20 years of experience, Multicare has become one of the top five branded generic companies in the Philippines, committed to improving patient outcomes through its extensive product portfolio. (multicare.com.ph)

2Distribution Network

Multicare Pharmaceuticals Philippines, Inc. maintains its primary operations at 17th Floor Units A & B, 8 Rockwell Building, Hidalgo Drive, Rockwell Center, Makati City 1226, Philippines. (multicare.com.ph) While specific details about its warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic alliance with Lupin Limited suggests a robust distribution network capable of efficiently delivering products across the Philippines. This partnership likely enhances Multicare's logistics capabilities, ensuring timely and reliable supply to meet the demands of the Philippine market.

3Industry Role

Multicare Pharmaceuticals Philippines, Inc. plays a significant role in the Philippine pharmaceutical supply chain as a primary wholesaler and distributor. By importing and marketing a wide range of pharmaceutical products, the company ensures the availability of essential medicines to healthcare providers and patients nationwide. Its strategic alliance with Lupin Limited further strengthens its position, enabling Multicare to offer a diverse portfolio of high-quality branded generics, thereby contributing to the accessibility and affordability of healthcare in the Philippines. (multicare.com.ph)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Multicare Pharmaceuticals Philippin

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Multicare Pharmaceuticals Philippines, Inc. demonstrates a high level of sourcing concentration, with a total import value of $1.8 million USD from India across 60 shipments. The top five imported products—Carboplatin, Febuxostat, Letrozole, Cytarabine, and Dacarbazine—account for 100% of the company's imports from India. This indicates a strategic focus on specific high-demand oncology and lipid & metabolism products. The primary supplier, NAPROD LIFE SCIENCES PRIVATE LIMITED, accounts for 88.2% of the shipments, suggesting a strong and stable relationship. The involvement of other suppliers like LUPIN LIMITED and OLIVE HEALTHCARE indicates a diversified sourcing strategy, mitigating potential risks associated with single-source dependency.

2Supply Chain Resilience

The resilience of Multicare Pharmaceuticals Philippines, Inc.'s supply chain is bolstered by its diversified supplier base, including NAPROD LIFE SCIENCES PRIVATE LIMITED, LUPIN LIMITED, and OLIVE HEALTHCARE. This diversification reduces the risk of supply disruptions. The company's focus on finished pharmaceutical formulations, rather than raw APIs or bulk drugs, suggests a streamlined supply chain that emphasizes the importation of ready-to-market products. While specific details about backup suppliers and shipping routes are not publicly available, the strategic alliance with Lupin Limited likely provides additional support and stability to Multicare's supply chain operations.

Importing Pharmaceuticals into Philippines — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Philippines

1Regulatory Authority & Framework

In the Philippines, the Food and Drug Administration (FDA) is the primary regulatory body overseeing the importation, marketing, and distribution of pharmaceutical products. The FDA ensures that all imported medicines meet the required safety, efficacy, and quality standards before they are made available to the public. Key legislation governing pharmaceutical imports includes the Food and Drug Administration Act of 2009 (Republic Act No. 9711), which provides the legal framework for the FDA's operations and responsibilities. The marketing authorization pathway for Indian generics involves obtaining a Certificate of Product Registration (CPR) from the FDA, which requires submission of comprehensive documentation, including product dossiers, clinical data, and proof of Good Manufacturing Practice (GMP) compliance.

2Import Licensing & GMP

Import licensing requirements in the Philippines mandate that all pharmaceutical products, including those imported by companies like Multicare Pharmaceuticals Philippines, Inc., must be registered with the FDA and possess a valid Certificate of Product Registration (CPR). This process ensures that imported medicines comply with the FDA's safety, efficacy, and quality standards. The FDA recognizes GMP certificates from reputable regulatory bodies, such as the European Medicines Agency (EMA), World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian exporters seeking to supply Multicare must ensure that their manufacturing facilities hold valid GMP certifications from these recognized authorities. Additionally, wholesale distribution authorization is required for companies involved in the distribution of pharmaceutical products within the Philippines, ensuring compliance with local regulations and standards.

Multicare Pharmaceuticals Philippin — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Multicare Pharmaceuticals Philippines, Inc.'s product strategy focuses on therapeutic areas with high unmet medical needs, such as oncology and lipid & metabolism disorders. The company's importation of specific products like Carboplatin, Febuxostat, Letrozole, Cytarabine, and Dacarbazine aligns with this strategy, addressing critical health concerns prevalent in the Philippines. Market demand for these products is driven by the increasing incidence of cancer and metabolic diseases, necessitating access to effective and affordable treatments. By focusing on these therapeutic areas, Multicare aims to improve patient outcomes and contribute to the overall health and well-being of the Filipino population.

2Sourcing Profile

Multicare Pharmaceuticals Philippines, Inc. employs a sourcing strategy that emphasizes the importation of finished pharmaceutical formulations, particularly in the oncology and lipid & metabolism therapeutic areas. This approach allows the company to offer ready-to-market products, ensuring timely availability to meet patient needs. India plays a pivotal role in Multicare's procurement strategy, serving as a primary source of high-quality branded generics. The strategic alliance with Lupin Limited further enhances this sourcing profile, providing access to a diverse and reliable product portfolio.

Market Positioning

Seller's Guide — How to Become a Supplier to Multicare Pharmaceuticals Philippin

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Multicare Pharmaceuticals Philippines, Inc., particularly in therapeutic areas where Multicare seeks to expand its product portfolio. Gaps in Multicare's current sourcing may exist in emerging treatments or specialized formulations within oncology and lipid & metabolism disorders. Indian exporters can explore these opportunities by offering innovative products that align with Multicare's strategic focus and meet the evolving needs of the Philippine market. Establishing partnerships with Multicare can facilitate market entry and growth in the Southeast Asian region.

2Requirements & Qualifications

Indian exporters aiming to supply Multicare Pharmaceuticals Philippines, Inc. and the broader Philippine market must ensure that their manufacturing facilities hold valid Good Manufacturing Practice (GMP) certifications from recognized authorities such as the European Medicines Agency (EMA), World Health Organization (WHO), or the Pharmaceutical Inspection Co-operation Scheme (PIC/S).

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Multicare Pharmaceuticals Philippin

What products does Multicare Pharmaceuticals Philippin import from India?

Multicare Pharmaceuticals Philippin imports 5 pharmaceutical products across 3 categories. Top imports: Carboplatin ($786.8K), Febuxostat ($350.0K), Letrozole ($350.0K), Cytarabine ($291.6K), Dacarbazine ($65.9K).

Who supplies pharmaceuticals to Multicare Pharmaceuticals Philippin from India?

Multicare Pharmaceuticals Philippin sources from 3 verified Indian suppliers. The primary supplier is Naprod Life Sciences Private Limited (88.2% of imports, $3.0M).

What is Multicare Pharmaceuticals Philippin's total pharmaceutical import value?

Multicare Pharmaceuticals Philippin's total pharmaceutical import value from India is $1.8M, based on 60 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Multicare Pharmaceuticals Philippin focus on?

Multicare Pharmaceuticals Philippin imports across 3 categories. The largest: Oncology (42.7%), Advanced Oncology (38.4%), Lipid & Metabolism (19.0%).

Get Full Multicare Pharmaceuticals Philippin Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.